Northwest Biotherapeutics (NWBO) Return on Sales (2010 - 2026)

Northwest Biotherapeutics' Return on Sales history runs 17 years deep, the most recent figure standing at 0.27% for Q1 2026.

• On a quarterly basis, Return on Sales rose 24.0% year-over-year to 0.27% in Q1 2026; TTM through Mar 2026 was 0.47%, a 8.0% increase from a year earlier, with the FY2025 full-year figure at 0.44%, up 17.0% from the prior year.
• Return on Sales eased to 0.27% in Q1 2026 per NWBO's latest filing, from 0.24% in the prior quarter.
• Across five years, Return on Sales topped out at 0.16% in Q1 2023 and bottomed at 6.32% in Q3 2022.
• The 5-year median for Return on Sales is 0.47% (2022), against an average of 0.9%.
• Across the five-year window, Return on Sales plunged 599 bps in 2022 and jumped 594 bps in 2023, its largest moves.
• Year by year, Return on Sales stood at 0.33% in 2022, then increased by 17 bps to 0.27% in 2023, then tumbled by 322 bps to 1.14% in 2024, then surged by 79 bps to 0.24% in 2025, then slipped by 12 bps to 0.27% in 2026.
• Per Business Quant, the three latest NWBO Return on Sales figures stand at 0.27% (Q1 2026), 0.24% (Q4 2025), and 0.85% (Q3 2025).